The activity of plasminogen activators and inhibitors in the synovial fluid and plasma of patients with various forms of chronic arthritis was characterised. Tissue-type plasminogen activator antigen (t-PA:Ag), urokinase-type plasminogen activator antigen (u-PA:Ag), the proenzyme single chain u-PA (scu-PA), and plasminogen activator inhibitor (PAI) were measured in the synovial fluid and plasma of 22 patients with seropositive rheumatoid arthritis (RA), 13 with seronegative RA, and 23 patients with various forms of arthritis. In all patient groups the levels of t-PA:Ag in synovial fluid were lower and the levels of u-PA:Ag and PA higher than plasma levels. Synovial fluid u-PA was more activated than plasma u-PA. Comparison of the patient groups showed that the largest differences between fibrinolytic parameters in synovial fluid and plasma were present in patients with seropositive RA followed by patients with seronegative RA and patients with various forms of arthritis. This order paralleled the functional and radiological scores of joint destruction in the patient groups studied. The results of this study indicate that suppression of t-PA production and enhancement of u-PA synthesis and activation in arthritic joints are associated with the clinical severity ofarthritis.
Removal of fibrin may be crucial for the preservation of the function of arthritic joints. Fibrin degradation products have been demonstrated in arthritic synovial fluid, which suggests that fibrinolysis occurs in the joint cavity.' Indeed, the essential components of the fibrinolytic system are available in arthritic effusions. 27 Tissue-type plasminogen activator (t-PA) is produced in an active form and is rapidly neutralised by plasminogen activator inhibitor (PAI). In contrast, urokinase-type plasminogen activator (u-PA) is released in a latent form, single chain u-PA (scu-PA), which can be activated to two chain u-PA by trace amounts of plasmin.8 9 The two forms ofu-PA are detectable as u-PA antigen (u-PA:Ag) even when the activated form is bound to inhibitors.'0 The actual generation of plasmin, the proteolytic enzyme responsible for the breakdown of fibrin, has been witnessed in synovial fluid of patients with arthritis by the presence of plasminantiplasmin complexes.5
There is ample evidence that proteolytic enzymes play a part in the pathogenesis of joint destruction in patients with arthritis. Enzymes of the fibrinolytic system may contribute to the degradation of components of connective tissue. Plasmin has the capacity to degrade proteoglycans' 1-13 and to activate procollagenase to collagenase. '4 Changes in the concentration of fibrinolytic enzymes or their inhibitors may therefore be of significance for the pathogenesis of joint destruction in chronic arthritis. In this study we characterised the plasminogen activators in patients with several types of arthritis: t-PA:Ag, u-PA:Ag, and the concentration of PAI were measured in synovial fluid and plasma. The data were compared with those of plasma obtained from healthy subjects. Nine parts of synovial fluid were collected in one part of 0-11 mol/l sodium citrate. From all patients blood was obtained on the day of joint puncture. Plasma was prepared by centrifugation of cooled citrated blood (9:1). Plasma and synovial fluid were stored at -80°C until analysis.
Patients and methods
Plasma and synovial fluid u-PA:Ag and scu-PA were determined using a combination of an ELISA and a biological immunoassay.'0 The lower detection limit in our material was 01, 0-2, or 0-4 ng/ml, according to the dilution used, which depended on the available amount of plasma or synovial fluid (either 50, 25, or 12-5 1d, respectively).
Plasma and SF t-PA:Ag was assayed by an enzyme immunoassay, using antibodies to t-PA (Immulyse, Biopool, Umea, Sweden). PAI activity was measured by titration of diluted plasma with t-PA'9; results of PAI activity are expressed as a percentage of a standard plasma pool.
STATISTICAL ANALYSIS
Means and standard deviations were calculated after eliminating aberrant values according to the slippage test.20 21 Differences between .~compartments differed by at least a factor of 10 ( fig 1) .
Plasminogen activators in snoialfluid andplasma from patients uith arthritis tPercentage of a standard plasma pool. As for u-PA:Ag, the PAI concentrations in synovial fluid of all patient groups were significantly higher than in plasma (p<0005), whereas the differences between the patient groups did not differ significantly (table 3) .
ACTIVATION OF u-PA IN PLASMA AND SYNOVIAL FLUID
Not only total u-PA:Ag, but also scu-PA levels were significantly higher in synovial fluid than in plasma in all groups of patients with arthritis (p<O-OO1; tables 2 and 3). When scu-PA is activated to the active enzyme, the ratio of scu-PA to total u-PA:Ag in plasma or in synovial fluid will decrease. Consequently, this ratio can be regarded as a measure of the activation of u-PA. lower in synovial fluid than in plasma-that is, the degree of activation of u-PA was higher (p<0025; fig 2) . The degree of activation in plasma was significantly higher in patients with seropositive RA than in the other groups of patients with arthritis and higher than in healthy controls. In synovial fluid, differences between patients with seropositive RA and those with other forms of arthritis did not reach statistical significance.
Discussion
The results of this study show considerable differences between synovial fluid and plasma concentrations of the components of the fibrinolytic system in patients with arthritis. In synovial fluid the t-PA:Ag concentration was lower whereas the u-PA:Ag and PAI concentrations were higher than plasma levels. Consequently, the ratio of t-PA:Ag to u-PA:Ag was on average ten times lower in synovial fluid than in plasma. Furthermore, in all patient groups the mean ratio between scu-PA and u-PA:Ag was significantly lower in synovial fluid, which indicates a higher degree of u-PA activation in synovial fluid than in plasma. The effect of increased u-PA:Ag concentrations and increased u-PA activation in the arthritic joint is unclear. Fibrin is persistently present in synovial fluid, which suggests that u-PA is prevented from the complete activation of plasminogen and from dissolving fibrin. If the complementary and synergistic activation of fibrin bound plasminogen by u-PA and t-PA, as proposed by Gurewich,27 requires a certain balance between t-PA and u-PA, the disturbance of the normal ratio could reduce the fibrinolytic potential. The high levels of PAI found in the synovial fluid of arthritic joints may also contribute to the incomplete effect of the plasminogen activators on fibrin dissolution as fibrinolytic activity is greatly influenced by PAI activity.28 29 Differences in the synovial fluid fibrinolytic parameters between patient groups with various forms of inflammatory arthritis have not previously been reported. The ratio t-PA:Ag/u-PA:Ag and the activation of u-PA in the group of patients with arthritis paralleled the functional and radiological scores ofjoint destruction. This relation may be secondary to differences in the production of cytokines. It has been shown that interleukin I and tumour necrosis factor stimulate the production of u-PA:Ag and PAI Synovial fluid u-PA activity can be reduced by the administration of inhibitors. Administration of u-PA inhibitors to experimental animal models of arthritis suggests that such treatment may protect against joint destruction. Preliminary studies in patients with RA and osteoarthritis have shown that intra-articular injections of u-PA inhibitors lead to a significant reduction in local u-PA activity.6 36 The results of this study support the hypothesis that changes in the concentration of plasminogen activators are of pathophysiological significance for joint destruction in arthritis. It remains to be established whether normalisation of the t-PA to u-PA ratio and the degree of activation of u-PA can reduce the severity of joint lesions in patients with chronic arthritis.
